Robert Glazer - Concepedia

Author

Robert Glazer

Novartis (United States)

Also Known As

R D Glazer, R GLAZER, R Glazer, R. D. Glazer, R. Glazer, R.D. Glazer, Robert D. Glazer, Robert Glazer

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Novartis (Switzerland)Mario Negri Institute for Pharmacological Research Tris Pharma (United States)University of Minnesota

About

Robert Glazer is an author at Novartis (United States) specializing in medicine, cardiovascular pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	1.7K
2	Pharmacology	10	10	855
3	Public Health	3	3	507
4	Emergency Medicine	2	2	99
5	Geriatrics	1	1	39

Robert Glazer

Publications

Citations

H-Index

Page 1

	Year	Citations
Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) Inder S. Anand, Lloyd D. Fisher, YannTong Chiang, Circulation	2003	860
C-Reactive Protein in Heart Failure Inder S. Anand, Roberto Latini, Viorel G. Florea, Circulation	2005	444
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT) Aldo P. Maggioni, Roberto Latini, Peter E. Carson, American Heart Journal Heart FailureCardiac AnaesthesiaCardiovascular DiseaseCardiovascular PharmacologyPharmacotherapy	2005	409
Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure Inder S. Anand, Michael A. Kuskowski, Thomas S. Rector, Circulation	2005	290
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension Thomas Philipp, Timothy R. Smith, Robert Glazer, Clinical Therapeutics HypertensionCardiovascular DiseaseAntihypertensive TherapyAdult PatientsPharmacology	2007	260
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure Maylene Wong, Lidia Staszewsky, Roberto Latini, Journal of the American College of Cardiology Heart FailureStructural Heart DiseaseCardiovascular DiseaseOutcomes ResearchDefines Outcomes	2004	221
Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide David A. Calhoun, Yves Lacourcière, Yann Tong Chiang, Hypertension	2009	184
Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure Jay N. Cohn, Gianni Tognoni, Robert Glazer, Journal of Cardiac Failure HypertensionHeart FailureCardiovascular DiseaseAntihypertensive TherapyPharmacology	1999	146
Valsartan: Preclinical and Clinical Profile of an Antihypertensive Angiotensin‐II Antagonist Leoluca Criscione, William A. Bradley, Peter Bühlmayer, Cardiovascular Drug Reviews Molecular PharmacologyHypertensionAntihypertensive TherapyAntihypertensive Angiotensin‐ii AntagonistVascular Pharmacology	1995	132
Effect of Valsartan Added to Background ACE Inhibitor Therapy in Patients with Heart Failure: Results from Val-HeFT Henry Krum, Peter E. Carson, Csaba Farsang, European Journal of Heart Failure	2004	98

Page 1